Brain Age Prediction Reveals Aberrant Brain White Matter in Schizophrenia and Bipolar Disorder: A Multisample Diffusion Tensor Imaging Study.


Journal

Biological psychiatry. Cognitive neuroscience and neuroimaging
ISSN: 2451-9030
Titre abrégé: Biol Psychiatry Cogn Neurosci Neuroimaging
Pays: United States
ID NLM: 101671285

Informations de publication

Date de publication:
12 2020
Historique:
received: 06 01 2020
revised: 15 06 2020
accepted: 26 06 2020
pubmed: 30 8 2020
medline: 28 4 2021
entrez: 30 8 2020
Statut: ppublish

Résumé

Schizophrenia (SZ) and bipolar disorder (BD) share substantial neurodevelopmental components affecting brain maturation and architecture. This necessitates a dynamic lifespan perspective in which brain aberrations are inferred from deviations from expected lifespan trajectories. We applied machine learning to diffusion tensor imaging (DTI) indices of white matter structure and organization to estimate and compare brain age between patients with SZ, patients with BD, and healthy control (HC) subjects across 10 cohorts. We trained 6 cross-validated models using different combinations of DTI data from 927 HC subjects (18-94 years of age) and applied the models to the test sets including 648 patients with SZ (18-66 years of age), 185 patients with BD (18-64 years of age), and 990 HC subjects (17-68 years of age), estimating the brain age for each participant. Group differences were assessed using linear models, accounting for age, sex, and scanner. A meta-analytic framework was applied to assess the heterogeneity and generalizability of the results. Tenfold cross-validation revealed high accuracy for all models. Compared with HC subjects, the model including all feature sets significantly overestimated the age of patients with SZ (Cohen's d = -0.29) and patients with BD (Cohen's d = 0.18), with similar effects for the other models. The meta-analysis converged on the same findings. Fractional anisotropy-based models showed larger group differences than the models based on other DTI-derived metrics. Brain age prediction based on DTI provides informative and robust proxies for brain white matter integrity. Our results further suggest that white matter aberrations in SZ and BD primarily consist of anatomically distributed deviations from expected lifespan trajectories that generalize across cohorts and scanners.

Sections du résumé

BACKGROUND
Schizophrenia (SZ) and bipolar disorder (BD) share substantial neurodevelopmental components affecting brain maturation and architecture. This necessitates a dynamic lifespan perspective in which brain aberrations are inferred from deviations from expected lifespan trajectories. We applied machine learning to diffusion tensor imaging (DTI) indices of white matter structure and organization to estimate and compare brain age between patients with SZ, patients with BD, and healthy control (HC) subjects across 10 cohorts.
METHODS
We trained 6 cross-validated models using different combinations of DTI data from 927 HC subjects (18-94 years of age) and applied the models to the test sets including 648 patients with SZ (18-66 years of age), 185 patients with BD (18-64 years of age), and 990 HC subjects (17-68 years of age), estimating the brain age for each participant. Group differences were assessed using linear models, accounting for age, sex, and scanner. A meta-analytic framework was applied to assess the heterogeneity and generalizability of the results.
RESULTS
Tenfold cross-validation revealed high accuracy for all models. Compared with HC subjects, the model including all feature sets significantly overestimated the age of patients with SZ (Cohen's d = -0.29) and patients with BD (Cohen's d = 0.18), with similar effects for the other models. The meta-analysis converged on the same findings. Fractional anisotropy-based models showed larger group differences than the models based on other DTI-derived metrics.
CONCLUSIONS
Brain age prediction based on DTI provides informative and robust proxies for brain white matter integrity. Our results further suggest that white matter aberrations in SZ and BD primarily consist of anatomically distributed deviations from expected lifespan trajectories that generalize across cohorts and scanners.

Identifiants

pubmed: 32859549
pii: S2451-9022(20)30168-3
doi: 10.1016/j.bpsc.2020.06.014
pii:
doi:

Types de publication

Journal Article Meta-Analysis Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1095-1103

Subventions

Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/H008217/1
Pays : United Kingdom
Organisme : Medical Research Council
Pays : United Kingdom
Organisme : NIMH NIH HHS
ID : P50 MH071616
Pays : United States
Organisme : NIMH NIH HHS
ID : RL1 MH083268
Pays : United States
Organisme : NIMH NIH HHS
ID : RL1 MH083269
Pays : United States
Organisme : NIDA NIH HHS
ID : RL1 DA024853
Pays : United States
Organisme : NIMH NIH HHS
ID : RL1 MH083270
Pays : United States
Organisme : NLM NIH HHS
ID : RL1 LM009833
Pays : United States
Organisme : NIMH NIH HHS
ID : PL1 MH083271
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH056584
Pays : United States

Investigateurs

L Farde (L)
L Flyckt (L)
G Engberg (G)
S Erhardt (S)
H Fatouros-Bergman (H)
S Cervenka (S)
L Schwieler (L)
F Piehl (F)
I Agartz (I)
K Collste (K)
P Victorsson (P)
A Malmqvist (A)
M Hedberg (M)
F Orhan (F)
C Sellgren (C)

Informations de copyright

Copyright © 2020 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Auteurs

Siren Tønnesen (S)

Norwegian Centre for Mental Disorders Research (NORMENT), Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.

Tobias Kaufmann (T)

Norwegian Centre for Mental Disorders Research (NORMENT), Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.

Ann-Marie G de Lange (AG)

Norwegian Centre for Mental Disorders Research (NORMENT), Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Psychology, University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway; Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, United Kingdom.

Geneviève Richard (G)

Norwegian Centre for Mental Disorders Research (NORMENT), Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.

Nhat Trung Doan (NT)

Norwegian Centre for Mental Disorders Research (NORMENT), Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.

Dag Alnæs (D)

Norwegian Centre for Mental Disorders Research (NORMENT), Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway; Bjørknes University College, Oslo, Norway.

Dennis van der Meer (D)

Norwegian Centre for Mental Disorders Research (NORMENT), Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway; School of Mental Health and Neuroscience, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, the Netherlands.

Jaroslav Rokicki (J)

Norwegian Centre for Mental Disorders Research (NORMENT), Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Psychology, University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.

Torgeir Moberget (T)

Norwegian Centre for Mental Disorders Research (NORMENT), Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Psychology, University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.

Ivan I Maximov (II)

Norwegian Centre for Mental Disorders Research (NORMENT), Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Psychology, University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.

Ingrid Agartz (I)

Norwegian Centre for Mental Disorders Research (NORMENT), Institute of Clinical Medicine, University of Oslo, Oslo, Norway; KG Jebsen Centre for Neurodevelopmental Disorders, University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway; Department of Psychiatric Research, Diakonhjemmet Hospital, Oslo, Norway; Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm Region, Stockholm, Sweden; Stockholm Health Care Services, Stockholm Region, Stockholm, Sweden.

Sofie R Aminoff (SR)

Norwegian Centre for Mental Disorders Research (NORMENT), Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway; Early Intervention in Psychosis Advisory Unit for South East Norway, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.

Dani Beck (D)

Norwegian Centre for Mental Disorders Research (NORMENT), Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Psychology, University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.

Deanna M Barch (DM)

Department of Psychological and Brain Sciences, Washington University in St. Louis, St. Louis, Missouri; Department of Psychiatry, Washington University in St. Louis, St. Louis, Missouri; Department of Radiology, School of Medicine, Washington University in St. Louis, St. Louis, Missouri.

Justyna Beresniewicz (J)

Department of Biological and Medical Psychology, University of Bergen, Bergen, Norway; NORMENT, Haukeland University Hospital, Bergen, Norway.

Simon Cervenka (S)

Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm Region, Stockholm, Sweden; Stockholm Health Care Services, Stockholm Region, Stockholm, Sweden.

Helena Fatouros-Bergman (H)

Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm Region, Stockholm, Sweden; Stockholm Health Care Services, Stockholm Region, Stockholm, Sweden.

Alexander R Craven (AR)

Department of Biological and Medical Psychology, University of Bergen, Bergen, Norway; NORMENT, Haukeland University Hospital, Bergen, Norway; Department of Clinical Engineering, Haukeland University Hospital, Bergen, Norway.

Lena Flyckt (L)

Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm Region, Stockholm, Sweden; Stockholm Health Care Services, Stockholm Region, Stockholm, Sweden.

Tiril P Gurholt (TP)

Norwegian Centre for Mental Disorders Research (NORMENT), Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.

Unn K Haukvik (UK)

Norwegian Centre for Mental Disorders Research (NORMENT), Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Adult Psychiatry Unit, Department of Mental Health and Addiction, Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.

Kenneth Hugdahl (K)

Department of Biological and Medical Psychology, University of Bergen, Bergen, Norway; NORMENT, Haukeland University Hospital, Bergen, Norway; Department of Radiology, Haukeland University Hospital, Bergen, Norway; Department of Psychiatry, Haukeland University Hospital, Bergen, Norway.

Erik Johnsen (E)

Department of Clinical Medicine (K1), University of Bergen, Bergen, Norway.

Erik G Jönsson (EG)

Norwegian Centre for Mental Disorders Research (NORMENT), Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway; Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm Region, Stockholm, Sweden; Stockholm Health Care Services, Stockholm Region, Stockholm, Sweden.

Knut K Kolskår (KK)

Norwegian Centre for Mental Disorders Research (NORMENT), Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Psychology, University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway; Sunnaas Rehabilitation Hospital HF, Nesodden, Norway.

Rune Andreas Kroken (RA)

Department of Biological and Medical Psychology, University of Bergen, Bergen, Norway; NORMENT, Haukeland University Hospital, Bergen, Norway.

Trine V Lagerberg (TV)

Norwegian Centre for Mental Disorders Research (NORMENT), Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.

Else-Marie Løberg (EM)

Department of Clinical Psychology, University of Bergen, Bergen, Norway; NORMENT, Haukeland University Hospital, Bergen, Norway; Department of Addiction Medicine, Haukeland University Hospital, Bergen, Norway.

Jan Egil Nordvik (JE)

Catosenteret Rehabilitation Center, Son, Norway.

Anne-Marthe Sanders (AM)

Norwegian Centre for Mental Disorders Research (NORMENT), Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Psychology, University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway; Sunnaas Rehabilitation Hospital HF, Nesodden, Norway.

Kristine Ulrichsen (K)

Norwegian Centre for Mental Disorders Research (NORMENT), Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Psychology, University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway; Sunnaas Rehabilitation Hospital HF, Nesodden, Norway.

Ole A Andreassen (OA)

Norwegian Centre for Mental Disorders Research (NORMENT), Institute of Clinical Medicine, University of Oslo, Oslo, Norway; KG Jebsen Centre for Neurodevelopmental Disorders, University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.

Lars T Westlye (LT)

Norwegian Centre for Mental Disorders Research (NORMENT), Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Psychology, University of Oslo, Oslo, Norway; KG Jebsen Centre for Neurodevelopmental Disorders, University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway. Electronic address: l.t.westlye@psykologi.uio.no.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH